CXCR4 and Beta-Receptor Inhibition for Stem Cell Mobilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current G-CSF regimens for hematopoietic stem cell mobilization are associated with adverse side effects and fail to achieve the required target cell dose in a significant portion of patients, particularly in non-Hodgkin's lymphoma and multiple myeloma patients.
Innovation Solution
Combining G-CSF with GPC-100, a CXCR4 antagonist, and propranolol, a beta-adrenergic receptor inhibitor, to enhance stem cell mobilization by modulating the CXCL12/CXCR4 axis, thereby increasing the number of mobilized white blood cells and progenitor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If G-CSF regimen is used for hematopoietic stem cell mobilization, then stem cell mobilization is achieved, but severe bone pain and failure to reach target cell dose occur in significant patients
Solution Approach 1:
The patent combines G-CSF with a CXCR4 antagonist (such as plerixafor or borixaxor) to create a dual-mechanism mobilization regimen. This combination targets both the granulocyte colony-stimulating pathway and the CXCL12/CXCR4 axis, achieving synergistic effects that reliably produce target cell doses while reducing reliance on high-dose G-CSF alone, thereby minimizing bone pain side effects
Solution Approach 2:
The patent modifies the mobilization approach by introducing CXCR4 antagonists that bind to the CXCR4 receptor, blocking the CXCL12 chemokine signal that retains stem cells in bone marrow. This parameter change in the mobilization mechanism allows for more predictable and reliable stem cell release into peripheral blood, achieving target cell doses with reduced adverse effects compared to G-CSF monotherapy
2Reliability
If G-CSF regimen is used for hematopoietic stem cell mobilization, then some stem cell mobilization occurs, but at least 15% of patients fail to produce the required target cell dose
Solution Approach 1:
The patent combines G-CSF with a CXCR4 antagonist to create a dual-mechanism mobilization regimen. This combination targets both the granulocyte colony-stimulating pathway and the CXCL12/CXCR4 axis, achieving synergistic effects that reliably produce target cell doses while reducing reliance on high-dose G-CSF alone, thereby minimizing bone pain side effects
Solution Approach 2:
The patent employs preliminary administration of CXCR4 antagonists before or concurrent with G-CSF to pre-block the CXCL12/CXCR4 retention axis. This preliminary action primes the bone marrow environment to facilitate more efficient stem cell mobilization in response to subsequent G-CSF stimulation, ensuring target cell dose achievement in previously treatment-resistant patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The triple combination significantly enhances white blood cell, lymphocyte, and progenitor cell mobilization, achieving comparable results to standard of care with reduced adverse effects and improved cell counts, particularly in lymphocyte mobilization.
Implementation Method 1
Blocking the CXCL12/CXCR4 axis can elicit rapid mobilization of HSC from bone marrow to the peripheral blood
Implementation Method 2
daily administration of propranolol, a beta-adrenergic receptor inhibitor, was shown to restore bone marrow function and increase erythroid progenitor colony growth
Data Source
AI summary
This invention relates to methods and compositions directed to mobilizing a cell in a subject by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is a stem cell. In some embodiments, the cell is an immune cell.